Inventor · disambiguated record
Daniel Olive
Also filed as: OLIVE DANIEL · OLIVE DANIEL R
30 granted patents·25 pending applications·373 citations·filing 1993–2024
96Inventor score
Files withINST NAT SANTE RECH MED17IMCHECK THERAPEUTICS SAS7OLIVE DANIEL7UNIV AIX MARSEILLE3EMERGENCE THERAPEUTICS GMBH2
Top patents by PatentIndex Score
55 records- 0198US8741295B2PD-1 antibodies and PD-L1 antibodies and uses thereofOLIVE DANIEL·Filed 2010·Granted Jun 3, 2014·87 cites·3 claims
- 0295US6739284B1Hummingbird feeder having removable vessel unitFiled 2002·Granted May 25, 2004·59 cites·10 claims
- 0393US9376493B2Antibodies directed against ICOS and uses thereofFAGET JULIEN·Filed 2012·Granted Jun 28, 2016·48 cites·4 claims
- 0490US9676852B2Antibodies directed against ICOS and uses thereofINSERM (INSTITUT NAT DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2016·Granted Jun 13, 2017·8 cites·17 claims
- 0589US11180556B2Antibodies directed against ICOS and uses thereofINST NAT SANTE RECH MED·Filed 2018·Granted Nov 23, 2021·2 cites·8 claims
- 0689US10745482B2Antibodies directed against ICOS and uses thereofINSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2019·Granted Aug 18, 2020·2 cites·7 claims
- 0789US7723482B2Anti-CD28 antibodyINST NAT SANTE RECH MED·Filed 2001·Granted May 25, 2010·52 cites·15 claims
- 0888US9975950B2Antibodies directed against ICOS and uses thereofINST NAT SANTE RECH MED·Filed 2017·Granted May 22, 2018·5 cites·17 claims
- 0986US5330285AApparatus for deflating tires of moving vehiclesSTOP STICK INC·Filed 1993·Granted Jul 19, 1994·59 cites·15 claims
- 1085US10675357B2Antibodies having specificity to nectin-4 and uses thereofINST NAT SANTE RECH MED·Filed 2016·Granted Jun 9, 2020·3 cites·14 claims
- 1184US10633446B2Antibodies directed against ICOS and uses thereofINST NAT SANTE RECH MED·Filed 2019·Granted Apr 28, 2020·1 cites·20 claims
- 1283US9695247B2Antibodies directed against ICOS for treating graft-versus-host diseaseINSERM (INSTITUT NAT DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2013·Granted Jul 4, 2017·5 cites·6 claims
- 1382US9637546B2PD-1 antibodies and PD-L1 antibodies and uses thereofUNIV AIX MARSEILLE·Filed 2014·Granted May 2, 2017·9 cites·5 claims
- 1481US10716838B2Anti-CD277 antibodiesOLIVE DANIEL·Filed 2019·Granted Jul 21, 2020·3 cites·12 claims
- 1581US9243052B2Method for treating and diagnosing hematologic malignanciesOLIVE DANIEL·Filed 2008·Granted Jan 26, 2016·14 cites·1 claims
- 1678US12049500B2Anti-nectin-4-antibodies and uses thereofEMERGENCE THERAPEUTICS GMBH·Filed 2022·Granted Jul 30, 2024·1 cites·20 claims
- 1778US11945871B2Anti-BTN3A antibodies and their use in treating cancer or infectious disordersIMCHECK THERAPEUTICS SAS·Filed 2023·Granted Apr 2, 2024·0 cites·14 claims
- 1877US8318166B2Ligands of HVEM for treating hematologic malignanciesOLIVE DANIEL·Filed 2008·Granted Nov 27, 2012·4 cites·2 claims
- 1975US9896507B2BTLA antibodies and uses thereofUNIV AIX MARSEILLE·Filed 2014·Granted Feb 20, 2018·3 cites·4 claims
- 2073US2020347134A1Antibodies Directed Against ICOS and Uses ThereofINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 2170US12419964B2Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payloadLILLY CO ELI·Filed 2024·Granted Sep 23, 2025·0 cites·11 claims
- 2269US11987631B2Anti-BTN3A antibodies and their use in treating cancer or infectious disordersIMCHECK THERAPEUTICS SAS·Filed 2019·Granted May 21, 2024·0 cites·14 claims
- 2368US2023272080A1Anti-btn3a antibodies and their use in treating cancer or infectious disordersIMCHECK THERAPEUTICS SAS·Filed 2022·Application pending·0 cites
- 2468US2024117041A1Antibodies having specificity for btn2 and uses thereofIMCHECK THERAPEUTICS SAS·Filed 2022·Application pending·0 cites
- 2565US2025197499A1Novel formats of anti-CD28/sPD-1 fusion constructsSTEALTH IO·Filed 2023·Application pending·0 cites
- 2664US2025018053A1Anti-nectin-4-antibodies and uses thereofEMERGENCE THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 2758US12247075B2BTN3A binding proteins and uses thereofIMCHECK THERAPEUTICS SAS·Filed 2019·Granted Mar 11, 2025·0 cites·9 claims
- 2858US11572409B2Antibodies having specificity for BTN2 and uses thereofIMCHECK THERAPEUTICS SAS·Filed 2018·Granted Feb 7, 2023·0 cites·6 claims
- 2957US10273306B2Antibodies directed against ICOS for treating graft-versus-host diseaseINST NAT SANTE RECH MED·Filed 2017·Granted Apr 30, 2019·0 cites·4 claims
- 3055US2018238888A1New biomarker for outcome in aml patientsINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 3155US2025129165A1Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disordersIMCHECK THERAPEUTICS·Filed 2022·Application pending·0 cites
- 3255US2023181753A1New method to treat cutaneous t-cell lymphomas and tfh derived lymphomasINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 3354US12398206B2Antibodies having specificity for nectin-4 and uses thereofUNIV DAIXMARSEILLE·Filed 2020·Granted Aug 26, 2025·0 cites·20 claims
- 3453US2023285527A1Anti-cd277 antibodies and uses thereofINSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE INERM·Filed 2022·Application pending·0 cites
- 3552US10005839B2Antagonist of the BTLA/HVEM interaction for use in therapyINST NAT SANTE RECH MED·Filed 2014·Granted Jun 26, 2018·0 cites·4 claims
- 3651US2024002522A1Anti-cd25 antibodiesINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 3751US2024002521A1Anti-cd25 antibodiesINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 3851US2017102389A1New biomarker for outcome in aml patientsINSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2015·Application pending·0 cites
- 3950US9266922B2Antigen peptide and uses thereofLOPEZ MARC·Filed 2012·Granted Feb 23, 2016·0 cites·2 claims
- 4050US2016082334A1Hybrid Game Board Apparatus for Bag Toss Play & CompetitionOLIVE DANIEL R·Filed 2014·Application pending·0 cites
- 4148US2012064096A1BTLA Antibodies and Uses ThereofOLIVE DANIEL·Filed 2010·Application pending·0 cites
- 4246US2016151489A1Combination of a ligand of hvem and an immunotoxin for use in therapyINSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE·Filed 2014·Application pending·0 cites
- 4345US11904004B2Anti-CD277 antibodiesINST NAT SANTE RECH MED·Filed 2020·Granted Feb 20, 2024·0 cites·11 claims
- 4445US2018155428A1BTLA Antibodies and Uses ThereofUNIV AIX MARSEILLE·Filed 2018·Application pending·0 cites
- 4544US2003113322A1CDR-H1-derived peptide CB11, pharmaceutical compositions made therefrom and methods of treating disorders in mammalsFiled 2002·Application pending·0 cites
- 4644US2016122434A1Antagonist of the btla/hvem interaction for use in therapyINSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE·Filed 2014·Application pending·0 cites
- 4744US2022251232A1Novel anti-cd25 antibodiesINSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICAL·Filed 2020·Application pending·0 cites
- 4842US12258400B2Antibodies having specificity for BTN2 and uses thereofIMCHECK THERAPEUTICS SAS·Filed 2020·Granted Mar 25, 2025·0 cites·14 claims
- 4942US2023183346A1Antibodies having specificity for btla and uses thereofINST NAT SANTE RECH MED·Filed 2017·Application pending·0 cites
- 5040US2018071413A1Non-invasive imaging of tumor pd-l1 expressionINST NAT SANTE RECH MED·Filed 2016·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel Olive files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →